May 17, 2022
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland    read more...
May 12, 2022
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress    read more...
May 05, 2022
BeiGene Reports First Quarter 2022 Financial Results    read more...
May 04, 2022
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)    read more...
Apr 29, 2022
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey    read more...
Apr 28, 2022
BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Waldenström’s Macroglobulinemia    read more...
Apr 27, 2022
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting    read more...
Apr 27, 2022
Global Phase 3 Trial of BeiGene’s PD-1 Inhibitor, Tislelizumab, in Combination with Chemotherapy Meets Primary Endpoint in First-Line Advanced Esophageal Squamous Cell Carcinoma    read more...
Apr 26, 2022
BeiGene Introduces Global Environmental, Social, and Governance Strategy    read more...
Apr 21, 2022
BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Cancer Patients and Communities in New Jersey    read more...
Apr 19, 2022
BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series    read more...
Apr 15, 2022
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma    read more...
Apr 11, 2022
IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Versus Ibrutinib in Final Response Analysis of ALPINE Trial in Chronic Lymphocytic Leukemia    read more...
Apr 08, 2022
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022    read more...
Apr 06, 2022
BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC    read more...
Mar 15, 2022
BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia    read more...
Mar 11, 2022
China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors    read more...
Mar 03, 2022
BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma    read more...
Mar 01, 2022
BeiGene to Present at the Cowen 42nd Annual Health Care Virtual Conference    read more...
Feb 25, 2022
BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results    read more...